FDA Clearance Tracker · P150003-S058
Synergy Everolimus-Eluting Platinum Chromium Coronary Stent System (Monorail and Over-The-Wire)
Last checked: Nov 20, 2026Latest source record: Aug 10, 2020 (this decision)Source: openFDAMethods & limitations
Decided
Aug 10, 2020
Approved
Time to decision
249 days
Received Dec 5, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P150003-S058
- Device name
- Synergy Everolimus-Eluting Platinum Chromium Coronary Stent System (Monorail and Over-The-Wire)
- Applicant
- Boston Scientific Corporation
- Applicant location
- Maple Grove, MN
- Received
- Dec 5, 2019
- Decided
- Aug 10, 2020
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P150003
Device type
- Device type
- Coronary drug-eluting stent (NIQ)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for the SYNERGY and SYNERGY XD Everolimus-Eluting Platinum Chromium Coronary Stent Systems.The SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System is indicated for improving luminal diameter in patients, including those at high risk for bleeding, with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non-ST elevation MI or documented silent ischemia due to atherosclerotic lesions in native coronary arteries >=2.25 mm to <= 5.00 mm in diameter in lesions <= 34 mm in length.The SYNERGY XD Everolimus-Eluting Platinum Chromium Coronary Stent System is indicated for improving luminal diameter in patients, including those at with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non-ST elevation MI or documented silent ischemia due to atherosclerotic lesions in native coronary arteries >= 2.25 mm to <= 5.00 mm in diameter in lesions <= 44 mm in length and for high risk bleeding patients with coronary arteries >= 2.25 mm to <= 5.00 mm in diameter in lesions <= 34 mm in length.
Source documents
Other decisions for Boston Scientific Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- SpaceOAR Flex System510(k)
K262151 · Decided Sep 11, 2026 · 78 days after receipt
Device type: Hydrogel Spacer (OVB) · Radiology & Imaging
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.